• About the PLAC^® Test
• PLAC Facts
• Basic Science
  of Lp-PLA₂
  • Lp-PLA₂ Resource Center
  • Mechanism of Action of Lp-PLA₂
• Ordering the PLAC Test
  • Inside United States
  • Outside United States
• Reimbursement
• Add to Mailing List

In this supplement to The American Journal of Cardiology, experts in the field of biomarkers, cardiovascular risk, and stroke have provided important reviews of the data on Lp-PLA₂.

In the first article, Dr. Howard S. Weintraub illuminates the identification of the vulnerable patient with rupture-prone plaque. Next, Drs. Amir Lerman and Joseph P. McConnell discuss the pathophysiology of Lp-PLA₂ and its direct causal role in vascular inflammation and plaque rupture. Then, Dr. Jeffrey L. Anderson reviews published studies on Lp-PLA₂ as a risk marker in the primary and secondary prevention of coronary and cardiovascular events. In the fourth article, the relation between Lp-PLA₂ measurement and stroke risk is explored by Dr. Philip Gorelick. Then, Dr. Marshall Corson et al provide a comprehensive review of the current literature and summarize the key points of the other authors in their articles in this supplement. Finally, recommendations by an expert panel on how Lp-PLA₂ testing might be used in conjunction with guideline-endorsed CVD risk assessment in an effort to create more aggressive risk reduction strategies.

To read the complete text of these articles, please click here to visit the American Journal of Cardiology website.